Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EM0477 / UNK||- / -|
Administered by: Other Purchased by: ??
Symptoms: Malaise, Nausea, SARS-CoV-2 test positive
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: CITALOPRAM
Preexisting Conditions: Medical History/Concurrent Conditions: COVID-19; Seizure; Vascular dementia
Diagnostic Lab Data: Test Date: 20201021; Test Name: COVID-19 virus test; Test Result: Positive
CDC 'Split Type': NLPFIZER INC2021191182
Write-up: Nausea; Malaise; This is a spontaneous report downloaded from the Medicines Agency regulatory authority-WEB [Lareb (LRB) number NL-LRB-00443788] from a contactable physician. An 84-year-old male patient received bnt162b2 (COMIRNATY) (lot# EM0477), via an unspecified route of administration, on 04Feb2021, at single dose, for COVID-19 immunisation. Medical history included vascular dementia from Sep2019, seizure from 12Jan2021, COVID-19 from 21Oct2020. Concomitant medication included citalopram (unknown manufacturer). The patient experienced nausea and malaise both on 04Feb2021 with fatal outcome in Feb2021 (within 8 days after vaccination). The patient underwent lab tests and procedures which included COVID-19 virus test: positive on 21Oct2020. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: Malaise; nausea
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166